INVALID TRIAL
CHIA and your personal trial have no criteria in common

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ - Patient has been permanently discontinued from   │ Patients who are currently receiving treatment     │      47 │
│ nilotinib treatment in the parent study due to     │ with any medications that have the potential to    │         │
│ unacceptable toxicity, non-compliance to study     │ prolong the QT interval or inducing Torsade de     │         │
│ procedures, withdrawal of consent or any other     │ Pointes and the treatment cannot be either safely  │         │
│ reason - Patient has participated in a Novartis    │ discontinued at least one week prior to nilotinib  │         │
│ sponsored combination trial where nilotinib was    │ treatment or switched to a different medication    │         │
│ dispensed in combination with another study        │ prior to start of nilotinib treatment and for the  │         │
│ medication and patient is still receiving          │ duration of the study                              │         │
│ combination therapy -Patients who are currently    │                                                    │         │
│ receiving treatment with any medications that have │                                                    │         │
│ the potential to prolong the QT interval or        │                                                    │         │
│ inducing Torsade de Pointes and the treatment      │                                                    │         │
│ cannot be either safely discontinued at least one  │                                                    │         │
│ week prior to nilotinib treatment or switched to a │                                                    │         │
│ different medication prior to start of nilotinib   │                                                    │         │
│ treatment and for the duration of the study        │                                                    │         │
│ -Pregnant or nursing (lactating) women, where      │                                                    │         │
│ pregnancy is defined as the state of a female      │                                                    │         │
│ after conception and until the termination of      │                                                    │         │
│ gestation, confirmed by a positive hcG laboratory  │                                                    │         │
│ test. -Women of child-bearing potential, defined   │                                                    │         │
│ as all women physiologically capable of becoming   │                                                    │         │
│ pregnant, unless they are using highly effective   │                                                    │         │
│ methods of contraception during the study and for  │                                                    │         │
│ 30 days after the final dose of nilotinib          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ -Patient is currently enrolled in a Novartis-      │ Patient is currently enrolled in a Novartis-       │      49 │
│ sponsored, Oncology Clinical Development \&        │ sponsored, Oncology Clinical Development & Medical │         │
│ Medical Affairs study receiving nilotinib and has  │ Affairs study receiving nilotinib and has          │         │
│ fulfilled all their requirements in the parent     │ fulfilled all their requirements in the parent     │         │
│ study -Patient is currently benefiting from the    │ study                                              │         │
│ treatment with nilotinib, as determined by the     │                                                    │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ -Patient is currently enrolled in a Novartis-      │ Patient is currently benefiting from the treatment │      29 │
│ sponsored, Oncology Clinical Development \&        │ with nilotinib, as determined by the investigator  │         │
│ Medical Affairs study receiving nilotinib and has  │                                                    │         │
│ fulfilled all their requirements in the parent     │                                                    │         │
│ study -Patient is currently benefiting from the    │                                                    │         │
│ treatment with nilotinib, as determined by the     │                                                    │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ -Patient is currently enrolled in a Novartis-      │ Willingness and ability to comply with scheduled   │      30 │
│ sponsored, Oncology Clinical Development \&        │ visits, treatment plans and any other study        │         │
│ Medical Affairs study receiving nilotinib and has  │ procedures                                         │         │
│ fulfilled all their requirements in the parent     │                                                    │         │
│ study -Patient is currently benefiting from the    │                                                    │         │
│ treatment with nilotinib, as determined by the     │                                                    │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ -Patient is currently enrolled in a Novartis-      │ Patient has demonstrated compliance, as assessed   │      32 │
│ sponsored, Oncology Clinical Development \&        │ by the investigator, with the parent study         │         │
│ Medical Affairs study receiving nilotinib and has  │ protocol requirements                              │         │
│ fulfilled all their requirements in the parent     │                                                    │         │
│ study -Patient is currently benefiting from the    │                                                    │         │
│ treatment with nilotinib, as determined by the     │                                                    │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ -Patient is currently enrolled in a Novartis-      │ Pregnant or nursing (lactating) women, where       │      34 │
│ sponsored, Oncology Clinical Development \&        │ pregnancy is defined as the state of a female      │         │
│ Medical Affairs study receiving nilotinib and has  │ after conception and until the termination of      │         │
│ fulfilled all their requirements in the parent     │ gestation, confirmed by a positive hcG laboratory  │         │
│ study -Patient is currently benefiting from the    │ test                                               │         │
│ treatment with nilotinib, as determined by the     │                                                    │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ -Patient is currently enrolled in a Novartis-      │ Women of child-bearing potential, defined as all   │      35 │
│ sponsored, Oncology Clinical Development \&        │ women physiologically capable of becoming          │         │
│ Medical Affairs study receiving nilotinib and has  │ pregnant, unless they are using highly effective   │         │
│ fulfilled all their requirements in the parent     │ methods of contraception during the study and for  │         │
│ study -Patient is currently benefiting from the    │ 30 days after the final dose of nilotinib          │         │
│ treatment with nilotinib, as determined by the     │                                                    │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ -Patient is currently enrolled in a Novartis-      │ Patient has participated in a Novartis sponsored   │      38 │
│ sponsored, Oncology Clinical Development \&        │ combination trial where nilotinib was dispensed in │         │
│ Medical Affairs study receiving nilotinib and has  │ combination with another study medication and      │         │
│ fulfilled all their requirements in the parent     │ patient is still receiving combination therapy     │         │
│ study -Patient is currently benefiting from the    │                                                    │         │
│ treatment with nilotinib, as determined by the     │                                                    │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ -Patient is currently enrolled in a Novartis-      │ Written informed consent obtained prior to         │      43 │
│ sponsored, Oncology Clinical Development \&        │ enrolling in roll-over studyPatient has been       │         │
│ Medical Affairs study receiving nilotinib and has  │ permanently discontinued from nilotinib treatment  │         │
│ fulfilled all their requirements in the parent     │ in the parent study due to unacceptable toxicity,  │         │
│ study -Patient is currently benefiting from the    │ non-compliance to study procedures, withdrawal of  │         │
│ treatment with nilotinib, as determined by the     │ consent or any other reason                        │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ - Patient has been permanently discontinued from   │ Patients who are currently receiving treatment     │      47 │
│ nilotinib treatment in the parent study due to     │ with any medications that have the potential to    │         │
│ unacceptable toxicity, non-compliance to study     │ prolong the QT interval or inducing Torsade de     │         │
│ procedures, withdrawal of consent or any other     │ Pointes and the treatment cannot be either safely  │         │
│ reason - Patient has participated in a Novartis    │ discontinued at least one week prior to nilotinib  │         │
│ sponsored combination trial where nilotinib was    │ treatment or switched to a different medication    │         │
│ dispensed in combination with another study        │ prior to start of nilotinib treatment and for the  │         │
│ medication and patient is still receiving          │ duration of the study                              │         │
│ combination therapy -Patients who are currently    │                                                    │         │
│ receiving treatment with any medications that have │                                                    │         │
│ the potential to prolong the QT interval or        │                                                    │         │
│ inducing Torsade de Pointes and the treatment      │                                                    │         │
│ cannot be either safely discontinued at least one  │                                                    │         │
│ week prior to nilotinib treatment or switched to a │                                                    │         │
│ different medication prior to start of nilotinib   │                                                    │         │
│ treatment and for the duration of the study        │                                                    │         │
│ -Pregnant or nursing (lactating) women, where      │                                                    │         │
│ pregnancy is defined as the state of a female      │                                                    │         │
│ after conception and until the termination of      │                                                    │         │
│ gestation, confirmed by a positive hcG laboratory  │                                                    │         │
│ test. -Women of child-bearing potential, defined   │                                                    │         │
│ as all women physiologically capable of becoming   │                                                    │         │
│ pregnant, unless they are using highly effective   │                                                    │         │
│ methods of contraception during the study and for  │                                                    │         │
│ 30 days after the final dose of nilotinib          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ -Patient is currently enrolled in a Novartis-      │ Patient is currently enrolled in a Novartis-       │      49 │
│ sponsored, Oncology Clinical Development \&        │ sponsored, Oncology Clinical Development & Medical │         │
│ Medical Affairs study receiving nilotinib and has  │ Affairs study receiving nilotinib and has          │         │
│ fulfilled all their requirements in the parent     │ fulfilled all their requirements in the parent     │         │
│ study -Patient is currently benefiting from the    │ study                                              │         │
│ treatment with nilotinib, as determined by the     │                                                    │         │
│ investigator -Patient has demonstrated compliance, │                                                    │         │
│ as assessed by the investigator, with the parent   │                                                    │         │
│ study protocol requirements -Willingness and       │                                                    │         │
│ ability to comply with scheduled visits, treatment │                                                    │         │
│ plans and any other study procedures -Written      │                                                    │         │
│ informed consent obtained prior to enrolling in    │                                                    │         │
│ roll-over study                                    │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 100
Average Levenshtein Ratio of individual lines: 39.36363636363637
OverAll Ratio: 69.68181818181819
